GEM Asset Management LLC Decreases Holdings in Eli Lilly and Company $LLY

GEM Asset Management LLC decreased its position in shares of Eli Lilly and Company (NYSE:LLY) by 6.3% during the 2nd quarter, Holdings Channel.com reports. The fund owned 854 shares of the company’s stock after selling 57 shares during the period. GEM Asset Management LLC’s holdings in Eli Lilly and Company were worth $660,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. WestEnd Advisors LLC lifted its stake in Eli Lilly and Company by 210.0% in the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock valued at $26,000 after buying an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC purchased a new stake in Eli Lilly and Company in the 1st quarter valued at approximately $27,000. Citizens National Bank Trust Department lifted its stake in Eli Lilly and Company by 180.0% in the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock valued at $35,000 after buying an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. purchased a new stake in Eli Lilly and Company in the 1st quarter valued at approximately $40,000. Finally, Mascagni Wealth Management Inc. purchased a new stake in Eli Lilly and Company in the 4th quarter valued at approximately $43,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 0.9%

Shares of Eli Lilly and Company stock opened at $748.26 on Tuesday. The business has a 50-day moving average of $740.54 and a 200-day moving average of $774.30. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The company has a market capitalization of $708.20 billion, a PE ratio of 48.91, a P/E/G ratio of 1.05 and a beta of 0.47. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $939.86.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company’s revenue was up 37.6% on a year-over-year basis. During the same period last year, the firm earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th were paid a dividend of $1.50 per share. The ex-dividend date was Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 39.22%.

Insider Activity at Eli Lilly and Company

In related news, CEO David A. Ricks purchased 1,632 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the transaction, the chief executive officer owned 546,601 shares of the company’s stock, valued at approximately $352,431,926.77. This trade represents a 0.30% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Daniel Skovronsky purchased 1,000 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The shares were bought at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the transaction, the executive vice president directly owned 137,660 shares of the company’s stock, valued at approximately $87,331,504. The trade was a 0.73% increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 4,514 shares of company stock valued at $2,894,841. 0.14% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research firms recently issued reports on LLY. Daiwa America lowered Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 17th. Deutsche Bank Aktiengesellschaft cut their price target on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a report on Monday, August 11th. Leerink Partnrs downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 7th. HSBC upgraded Eli Lilly and Company from a “reduce” rating to a “hold” rating and boosted their price target for the company from $675.00 to $700.00 in a report on Wednesday, August 27th. Finally, Leerink Partners reiterated a “market perform” rating and issued a $715.00 price target on shares of Eli Lilly and Company in a report on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus price target of $941.35.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.